JP2014516407A5 - - Google Patents

Download PDF

Info

Publication number
JP2014516407A5
JP2014516407A5 JP2014503629A JP2014503629A JP2014516407A5 JP 2014516407 A5 JP2014516407 A5 JP 2014516407A5 JP 2014503629 A JP2014503629 A JP 2014503629A JP 2014503629 A JP2014503629 A JP 2014503629A JP 2014516407 A5 JP2014516407 A5 JP 2014516407A5
Authority
JP
Japan
Prior art keywords
seq
derived
human
protein
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014503629A
Other languages
English (en)
Japanese (ja)
Other versions
JP6227523B2 (ja
JP2014516407A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2012/050352 external-priority patent/WO2012138284A1/en
Publication of JP2014516407A publication Critical patent/JP2014516407A/ja
Publication of JP2014516407A5 publication Critical patent/JP2014516407A5/ja
Application granted granted Critical
Publication of JP6227523B2 publication Critical patent/JP6227523B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014503629A 2011-04-05 2012-03-30 治療の方法においておよび化合物のスクリーニングのために有用なアミロドーシスターゲット Expired - Fee Related JP6227523B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1150299-4 2011-04-05
SE1150299 2011-04-05
PCT/SE2012/050352 WO2012138284A1 (en) 2011-04-05 2012-03-30 Amyloidosis target useful in methods of treatment and for screening of compounds

Publications (3)

Publication Number Publication Date
JP2014516407A JP2014516407A (ja) 2014-07-10
JP2014516407A5 true JP2014516407A5 (https=) 2015-05-14
JP6227523B2 JP6227523B2 (ja) 2017-11-08

Family

ID=46085122

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014503629A Expired - Fee Related JP6227523B2 (ja) 2011-04-05 2012-03-30 治療の方法においておよび化合物のスクリーニングのために有用なアミロドーシスターゲット

Country Status (4)

Country Link
US (1) US9522170B2 (https=)
EP (1) EP2694977B1 (https=)
JP (1) JP6227523B2 (https=)
WO (1) WO2012138284A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102300582A (zh) 2009-01-30 2011-12-28 阿尔法贝塔公司 用于治疗阿尔茨海默病的化合物和方法
JP7158420B2 (ja) * 2017-02-24 2022-10-21 アルツェオン・インコーポレーテッド 神経変性障害を処置するための方法
WO2021140140A1 (en) 2020-01-08 2021-07-15 Alphabeta Ab Compound and method for treatment of alzheimer's disease

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0290516A4 (en) 1986-10-24 1989-11-14 Jeffrey A Whitsett PROTEINS RELATED TO SURFACE-EFFECTIVE HYDROPHOBIC LUNG ACTIVE SUBSTANCES.
IL142852A0 (en) 1998-10-30 2002-03-10 Holtzman Jordan L A COMPLEX OF A CHAPERONE WITH β-AMYLOID AND METHODS EMPLOYING THIS COMPLEX
US6670195B1 (en) * 1999-05-26 2003-12-30 New York University Mutant genes in Familial British Dementia and Familial Danish Dementia
US20030224982A1 (en) 2001-07-05 2003-12-04 Li Li Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6673545B2 (en) 2000-07-28 2004-01-06 Incyte Corporation Prostate cancer markers
US6716589B2 (en) 2000-11-20 2004-04-06 Alphabeta Ab Discordant helix stabilization for prevention of amyloid formation
EP1387678A1 (en) 2001-05-03 2004-02-11 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
WO2003090682A2 (en) 2002-04-25 2003-11-06 The Scripps Research Institute Treatment and prevention of pulmonary conditions
WO2004056310A2 (en) 2002-12-09 2004-07-08 Children's Hospital Medical Center Methods of diagnosis and treatment of interstitial lung disease
CA2537844A1 (en) * 2003-09-05 2005-03-17 Cellzome Ag Treatment of neurodegenerative diseases
WO2005023858A1 (en) * 2003-09-05 2005-03-17 Cellzome Ag Protein complexes associated with app-processing
JP4796967B2 (ja) * 2003-11-07 2011-10-19 ヴァーミリオン インコーポレイテッド アルツハイマー病のためのバイオマーカー
AU2004296206A1 (en) 2003-12-04 2005-06-23 The Scripps Research Institute Treatment and preventions of asthma
CA2579710C (en) 2004-04-05 2013-01-08 The University Of Tokushima Antigen-drug vehicle enabling transmucosal and transdermal administration, and method of inducing mucosal immunity and mucosal vaccine and dds using the same
AU2006259482A1 (en) 2005-06-14 2006-12-28 Albert Einstein College Of Medicine Of Yeshiva University Effect of BRI proteins on abeta production
WO2007005672A2 (en) 2005-06-30 2007-01-11 The Scripps Research Institute Treatment and prevention of respiratory diseases and conditions
EP1930025B1 (en) 2005-08-05 2013-05-01 The University of Tokushima ANTIGEN-AND-DRUG VEHICLE WHICH ENABLES THE CHANGEOVER FROM THE SELECTIVE PRODUCTION OF IgA ANTIBODY TO THE PRODUCTION OF BOTH OF IgA AND IgG ANTIBODIES, AND TRANSNASAL/TRANSMUCOSAL VACCINE USING THE VEHICLE
JP4981305B2 (ja) * 2005-11-11 2012-07-18 公益財団法人大阪バイオサイエンス研究所 アルツハイマー病の発症リスク又はアルツハイマー病発症予後の予測方法
CA2706535A1 (en) 2006-11-22 2008-06-05 Albert Einstein College Of Medicine Of Yeshiva University Transgenic mammals modified in bri protein expression
US20100284969A1 (en) 2007-06-05 2010-11-11 Frank Guarnieri Methods and Compositions for Delivery of Medicaments to the Lungs
US20100298202A1 (en) 2007-07-06 2010-11-25 Mayo Foundation For Medical Education And Research Bri polypeptides and reducing ab aggregation
CN102300582A (zh) * 2009-01-30 2011-12-28 阿尔法贝塔公司 用于治疗阿尔茨海默病的化合物和方法
WO2011019082A1 (ja) * 2009-08-10 2011-02-17 独立行政法人科学技術振興機構 オートファジーの測定方法
WO2011162655A1 (en) * 2010-06-24 2011-12-29 Alphabeta Ab Compound and method for treatment of alzheimer's disease and familial dementia

Similar Documents

Publication Publication Date Title
Von Kobbe Targeting senescent cells: approaches, opportunities, challenges
Woodruff et al. The role of the complement system and the activation fragment C5a in the central nervous system
Lu et al. Targeting WWP1 ameliorates cardiac ischemic injury by suppressing KLF15-ubiquitination mediated myocardial inflammation
Lv et al. Klotho alleviates indoxyl sulfate-induced heart failure and kidney damage by promoting M2 macrophage polarization
EP2149584B1 (en) Method for enhancing immune response with peptide
JP2017158561A5 (https=)
WO2013043720A1 (en) Regulation of sodium channels by plunc proteins
CA3020580A1 (en) Peptide compounds to regulate the complement system
Wang et al. Let-7a gene knockdown protects against cerebral ischemia/reperfusion injury
Matharu et al. Development of retro-inverso peptides as anti-aggregation drugs for β-amyloid in Alzheimer's disease
EP3724232A1 (en) Exosome packaging and targeted autophagy
US9156889B2 (en) Drug transporter permeating blood-brain barrier, peptide and use thereof
Zhang et al. Neutrophil extracellular traps aggravate neuronal apoptosis and neuroinflammation via neddylation after traumatic brain injury
JP2014516407A5 (https=)
WO2017180841A1 (en) Treatment of cerebral cavernous malformations
Granic et al. LPYFDa neutralizes amyloid-β-induced memory impairment and toxicity
CN105745219B (zh) 结合β淀粉状蛋白的肽及其用于治疗和诊断阿尔茨海默痴呆症的用途
JP7820821B2 (ja) アルツハイマー病の治療のための化合物及び方法
CN107428811B (zh) 用于治疗和/或诊断阿尔茨海默氏痴呆症的特异性结合A-β-物类的肽
US20200031873A1 (en) Repurposing cell penetrating peptides and their novel derivatives and iopromide and iodo-aryl carbonates for treatment of senescence-related diseases and disorders
US10400009B2 (en) β-sheet breaker peptide used for preventing and/or treating alzheimer's disease
JP2016516756A (ja) 転移のインヒビター
WO2014060580A9 (en) Lxvp-mediated calcineurin inhibition in macrophages
AU2017222450A1 (en) Peptide inhibitors of calcium channels
JP2013545459A5 (https=)